Benzinga's Top #PreMarket Losers

Infinity Pharmaceuticals, Inc. INFI shares fell 12.52% to $14.26 in pre-market trading. Infinity Pharmaceuticals' Phase 2 study Of Duvelisib with background methotrexate in patients with moderate-to-severe rheumatoid arthritis did not meet primary endpoint. Insulet CorporationPODD shares dropped 7.93% to $41.00 in pre-market trading after the company lowered its FY2014 sales guidance. GW Pharmaceuticals PLC- ADRGWPH fell 6.44% to $66.48 in pre-market trading after the company issued an update on Epidilex. Sativex didn't meet primary endpoint in first trial. AmTrust Financial Services, Inc. AFSI shares dropped 4.57% to $51.53 in pre-market trading after the company announced the pricing of a three million share offering. Alexion Pharmaceuticals, Inc. ALXN shares declined 4.22% to $180.00 in pre-market trading after the company provided update on Phase 2 clinical trial with Eculizumab.